Expert Commentary
Challenges in Psychedelic Research Trials for Anxiety and Mood Disorders
Lori Davis, MD, of the University of Alabama at Birmingham describes methodological and clinical challenges in psychedelic research trials for anxiety and mood disorders. She discusses functional unblinding, expectancy bias, safety monitoring, and open questions about durability and implementation.
November 11, 2026
Lori Davis, MD, describes methodological, safety, and implementation challenges in psychedelic research trials for anxiety and mood disorders.
Expert Commentary
In this video, Lori Davis, MD, from the University of Alabama at Birmingham discusses challenges in psychedelic research trials. She situates the topic in the context of anxiety and mood disorders, stating that first-line treatments are only sixty percent effective and that investigators are looking for enhanced results with psychedelics.
She describes why psychedelic trials have inherent difficulties in rigorous scientific evaluation of efficacy and safety. Because psychedelic compounds are highly psychoactive, patients can often tell whether they received the compound or placebo, a problem she identifies as functional unblinding. She notes that clinical monitors may also recognize when a participant has experienced a psychedelic effect, and she describes the use of centralized independent raters who were not present during dosing and have no outside information about the participant’s experience to help mitigate this concern.
Dr Davis also discusses expectancy bias among participants entering psychedelic trials, as well as the challenge of distinguishing the effects of the compound from preparation, clinical supervision, and post-treatment follow-up. She emphasizes the need for substantial safety monitoring during dosing and follow-up, and she raises unresolved questions about dissemination, staffing, reimbursement, durability of benefit, and whether redosing may be needed at a later interval.
Key Takeaways
- Psychedelic research trials have inherent challenges in conducting rigorous scientific evaluation of efficacy and safety.
- Functional unblinding can occur because patients often can tell whether they received a psychedelic compound or placebo, and clinical monitors may also be able to tell that a participant experienced a psychedelic effect.
- Current trial methodology uses a centralized independent rater who is blind to treatment assignment, was not present during dosing, and has no outside information about the participant's experience to mitigate unblinding concerns.
- Expectancy bias is a challenge in psychedelic trials because participants may have high hopes for recovery and may be seeking access to compounds that are not yet FDA approved.
- Important unanswered questions include how long psychedelic effects last for anxiety and depression, whether redosing will be needed, and how strict clinical monitoring requirements may affect implementation, staffing, and reimbursement.
There’s also a lot of expectancy bias, meaning participants who are coming into a psychedelic research study have high hopes for recovery.
From Psychiatrist.com
Sign up for the JCP Digest
We send one focused email per month. No spam — unsubscribe anytime.
